ASCO 2020：11项华南地区研究入选口头报告，17项Poster报告

受世界新冠疫情不良影响，顺延于5翌年29日~6翌年2日在纽约市举行的澳大利亚流行病学研习（ASCO）例时会今年将首次以两条路线上形式举办，这是目前最大规模的两条路线上盛时会。现在，决议的概要题目公布，共计103个sessions，华北地区共计有11项科学研究入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨用以HER2+分散持续性丙型肺炎（PHOEBE）：一项III期随机试验持续性。

首站：分散持续性丙型肺炎

笔记：华北地区医学科学院公立医院徐兵河任教、马飞任教，北京大学原为公立医院胡夕春任教等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三中持续性丙型肺炎标准病人后卡培他滨维持节拍抗生素的III期试验持续性（SYSUCC-001）。

首站：丙型肺炎—大面积/区域/除此以外病人

笔记：中时会文系公共计卫生中时会心王树森任教等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用分散持续性脑部的表型外观上来预期脑部脊液中时会循环系统DNA检测的概率: 新物件对抗从前对手

首站：新物件解决从前问题

笔记：赵美芹 赵巴斯等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

了了非尼对毛里塔尼亚拉非尼作为中时会叶肺两条路线粒体肿瘤的三两条路线病人：一项解禁表单、随机、多中时会心II/III期试验持续性。

首站：肠肠胃肿瘤—肠胃腹腔、胰腺和自是

笔记：四川大学毛脉公立医院毕锋任教、华北地区人民解放军八一公立医院秦叔逵任教等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

华北地区中时会叶肺肿瘤高血压阿帕替尼二两条路线病人：一项随机、安慰剂依此、临床III期科学研究

首站：肠肠胃肿瘤—肠胃腹腔、胰腺和自是

笔记：华北地区人民解放军八一公立医院秦叔逵任教、四川大学毛脉公立医院赵秋任教等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中时会叶开刀持续性卵巢肿瘤二次两条路线粒体减灭术的一项随机III期试验持续性：SOC1 / SGOG-OV2。

研讨：小儿肿瘤症

笔记：北京大学原为中时会山公立医院臧荣余任教等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治持续性子宫切除术后除此以外病人中时会的序贯放抗生素对比单独恶持续性肿瘤或同步放抗生素（STARS科学研究）：一项随机、依此、解禁表单的III期试验持续性。

决议：小儿肿瘤症

笔记：中时会文系公共计卫生中时会心黄鹤任教、刘继红任教等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：除此以外吉非替尼对比抗生素用以可切除的EGFR持续性状的N1-N2期NSCLC-随机III期动物模型的最终总体穴居比对。

研讨：膀胱肿瘤—非小两条路线粒体大面积-区域/小两条路线粒体/其他胸部

笔记：东莞市人民公立医院吴一龙任教等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR持续性状无以分散非小两条路线粒体膀胱肿瘤高血压三两条路线酪氨酸腺苷抑制剂重新组建或不重新组建积极战场大面积恶持续性肿瘤：III期解禁表单流行病学随机试验持续性（SINDAS）的中时会期结果（NCT02893332）。

研讨：膀胱肿瘤-非小两条路线粒体分散

笔记：南充人民公立医院曾铭任教等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序持续性致死-1（PD-1）的人源化IgG4酵母重新组建阿昔替尼用以分散持续性呼吸道脑部瘤高血压的Ib期科学研究的总穴居期和动物标志物比对。

研讨：脑部瘤/皮肤肿瘤

笔记：北京大学公立医院郭军、盛锡楠任教等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容持续性和结果：通用CAR-T两条路线粒体首次人体试验持续性病人开刀/难治持续性T两条路线粒体急持续性淋巴两条路线粒体胃癌（r/r T-ALL）的相容持续性和。决议：整合中时会的病人技术-免疫病人。笔记：王欣欣等概要：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利霉素在中时会叶腹腔鳞状两条路线粒体肿瘤高血压中时会的应用：一项随机的解禁表单II期试验持续性（ORIENT-2）。决议：肠肠胃肿瘤-肠胃腹腔肿瘤、胰腺肿瘤和自是道肿瘤笔记：徐建明任教等概要：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D抗体CAR-T两条路线粒体对胃母两条路线粒体瘤的发挥作用持续性病人决议：中时会枢神经系统笔记：代红久、孙斌、杨东、徐晖、朱结缘、魏佳、郑旭东概要：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中时会叶错配修复原因高血压中时会的应用决议：整合中时会的病人学-免疫病人笔记：沈琳任教等概要：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病人开刀/难治持续性ACUTE淋巴两条路线粒体胃癌/淋巴瘤的唯一未人体动物模型决议: 整合持续性病人学-免疫病人笔记简介：张明志，杨林等概要：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）重新组建引入中时会叶实质上瘤高血压的Ib期科学研究决议：发展持续性病人学--分子基因表达药物和动物学笔记：龚继芳，沈琳任教等概要：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin重新组建紫杉醇和nedaplatin病人开刀持续性或分散持续性腹腔鳞状两条路线粒体肿瘤（ESCC）高血压的II期科学研究。决议：肠肠胃肿瘤-肠胃腹腔、胰腺和自是道肿瘤的科学研究笔记：王志强，赵玉红，王德申，王凤华，任超，谭琼 王志强、赵玉红、王德深、王凤华、任超、谭琼概要：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.决议：肠肠胃肿瘤-肠胃腹腔肿瘤、胰腺肿瘤和自是管肿瘤的二两条路线病人笔记：宋艳等概要：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种排泄物外体环状RNA分类器用以初始解剖时检测高等级肿瘤的排泄物外体环状RNA分类器：一项多中时会心的回顾持续性科学研究决议：循环系统系统生殖系统肿瘤症---肿瘤、睾丸肿瘤和肿瘤笔记简介：Liaoyuan Li等概要：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积中时会叶宫颈肿瘤并发抗生素后的除此以外抗生素决议: 小儿肿瘤症笔记简介： 赵珉珉等概要：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人甲状腺胃持续性肿瘤的相关持续性：基于ALTER01031试验持续性的比对。时会话：头颈部笔记：天津市公立医院高深任教概要：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼病人后高血压整部的不良影响: ALTER01031的亚组比对决议：头颈部笔记：天津市公立医院高深任教概要：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预期I-IIIA期非小两条路线粒体膀胱肿瘤（NSCLC）高血压术后开刀: GASTO1035和GASTO1018的结果决议：膀胱肿瘤-非小两条路线粒体大面积-世界持续性/小两条路线粒体/小两条路线粒体/其他胸科肿瘤症笔记：Si-Yu Wang等概要：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小两条路线粒体膀胱肿瘤（NSCLC）中时会EGFR酪氨酸腺苷抑制剂的新型耐药机制决议:膀胱肿瘤-非小两条路线粒体分散持续性膀胱肿瘤笔记简介：郑昕，金玲玲，满宇，欧真假，华宝，薛武，杨少，范敏 郑昕、金玲玲、满宇、欧真假、华宝、薛武、杨绍、范敏概要：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验持续性中时会中时会叶脑部瘤总穴居的替代终点决议：脑部瘤/皮肤肿瘤笔记：聂润聪，袁书强，赵元芳，陈英波，周志伟 聂润聪、袁书强、赵元芳、陈英波、周志伟概要：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人开刀或分散持续性原发持续性恶持续性骨高血压的II期科学研究决议： 溃疡笔记：唐丽娜，牛晓辉，陈毅，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶概要：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在中时会叶溃疡高血压多两条路线病人中时会的相容持续性和。决议：溃疡笔记：姚伟涛，的王室强，浙江余姚人，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、的王室强、浙江余姚人、王鑫、杜鑫辉、田志超、牛晓英概要：11526宣传品：414